Supernus (SUPN) Form 144 Shows Insider Sale and Recent 10b5-1 Dispositions
Rhea-AI Filing Summary
Form 144 filed for Supernus Pharmaceuticals, Inc. (SUPN) reports a proposed sale of 16,587 common shares with an aggregate market value of $763,665.48, representing securities listed on NASDAQ. The filing shows the shares were acquired and paid for on 09/22/2025 through exercise of stock options and paid in cash. The issuer’s outstanding common shares are reported as 56,073,088. The filing also discloses a series of prior 10b5-1 sales by JACK A KHATTAR over the past three months totaling 239,200 shares for gross proceeds of $10,414,682.10. The filer certifies no undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Positive
- Planned resale follows an option exercise and was paid in cash, showing a clear acquisition-to-sale chain.
- Multiple 10b5-1 sales are disclosed, indicating the sales were likely executed under pre-established trading plans.
- Filer included outstanding share count (56,073,088), allowing readers to contextualize the sale size.
Negative
- Insider sold a material block over three months (239,200 shares) totaling $10,414,682.10, which may be perceived negatively by some investors.
- Form 144 contains no operational or financial metrics, limiting the filing's usefulness for assessing company performance.
Insights
TL;DR: Routine insider sale following option exercise; substantial recent 10b5-1 dispositions but no new financial statements or forward guidance disclosed.
The Form 144 documents a proposed resale of 16,587 shares by a person who exercised stock options and paid cash on the same date, a common mechanism for insiders to monetize option exercises. The filing explicitly states the company's outstanding share count of 56,073,088, which places the proposed sale at a de minimis percentage of total shares outstanding. Notably, the filing catalogs multiple 10b5-1 sales by JACK A KHATTAR totaling 239,200 shares and $10,414,682.10 in gross proceeds over the past three months, indicating ongoing planned dispositions rather than ad-hoc sales. No revenue, earnings, or other operational metrics are provided in this notice; its informational value is limited to share movement and compliance representation.
TL;DR: Filing appears procedural and compliant, documenting exercise and planned resale with Rule 10b5-1 sales history.
The notice identifies the method of acquisition as an option exercise and confirms cash payment, and it lists the broker handling the resale. The inclusion of multiple dated 10b5-1 sales and the explicit representation that the seller does not possess undisclosed material information are consistent with standard disclosure and insider-trading compliance practices. This document does not show any qualifiers, legends, or indications of noncompliance within the text provided. Because the filing contains only sale-related facts and no material operational disclosures, its compliance implications are routine rather than indicative of regulatory concern.